Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination regimen used ...

A new decentralized exchange born from a collaboration between dYdX Labs and Robinhood Crypto is officially open for business. Arcus, which offers perpetual futures and tokenized equities, went live ...

The crypto protocol dYdX has rebranded as Arcus and is joining Robinhood’s new blockchain to bring perpetual and tokenized stock trading. The company behind the dYdX decentralized exchange (DEX) has ...

The ARCUS professional contoured circular saw blade from Arcus Inc. cuts arcs or circles from 30 in. to 30 ft. plus in diameter. Consists of a 7 1/4-in. contoured blade with 24 teeth, ATB, C-6 carbide ...

All the Latest Game Footage and Images from Arcus Chroma Say goodbye to jumping and hello to intense, lightning-fast grounded battles! Arcus Chroma is an offline juggle combo fighting game where ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Private equity investor Arcus Infrastructure Partners has bought a majority stake in regional aircraft lessor TrueNoord, its only current investment in the aviation sector. Arcus agreed to buy a 74% ...

Arcus Biosciences (RCUS) traded lower in the premarket on Monday after the oncology-focused biotech announced the discontinuation of a late-stage trial designed to evaluate its anti-TIGIT therapy ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

Arcobi combines 25 years of power market data with AI forecasting and automated execution, serving energy traders, generation operators, and commercial and industrial organizations. CALGARY, AB, March ...

Arcus Biosciences posted strong FY25 results, beating EPS and revenue estimates despite no commercial products and heavy R&D investment. RCUS’s valuation premium is driven by Casdatifan, a ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and ...